<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04025840</url>
  </required_header>
  <id_info>
    <org_study_id>2019-99</org_study_id>
    <nct_id>NCT04025840</nct_id>
  </id_info>
  <brief_title>Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery</brief_title>
  <official_title>Effect of Perioperative Epidural Block and Dexamethasone on Outcome of Patients Undergoing Pancreatic Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic cancer remains a devastating disease with an average 5-year survival rate of about
      3-5%. Previous retrospective studies showed that perioperative epidural block and/or
      dexamethasone are associated with improved outcome after cancer surgery. This randomized
      trial aims to investigate the effect of perioperative epidural block and/or dexamethasone on
      long-term survival in patients following pancreatic cancer surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is the fourth leading cause of cancer-related death in the world, and is
      estimated to become the second one in 2030. For patients with resectable pancreatic cancer,
      radical surgery is the first-line therapy. However, the clinical outcomes remain poor even
      after radical resection, as the incidence of postoperative morbidity is up to 50% and the
      5-year survival rate remains below 30%.

      For patients undergoing major intraabdominal surgery, epidural block may provide advantages
      by blocking the afferent nociceptive stimuli, providing better pain relief, decreasing opioid
      consumption, and alleviating stress response. These effects may be helpful in preserving
      immune function. Some retrospective studies showed that epidural block is associated with
      delayed cancer recurrence/metastasis and improved survival after cancer surgery.

      Low-dose dexamethasone is frequently used to prevent postoperative nausea and vomiting.
      Recent evidences from retrospective studies suggest that perioperative dexamethasone may also
      affect long-term outcome after cancer surgery. For example, in patients undergoing lung
      cancer surgery, intraoperative dexamethasone is associated with improved recurrence-free and
      overall survival. Similar results are also reported in patients after pancreatic cancer
      surgery.

      The investigators hypothesize that perioperative epidural block and dexamethasone may improve
      survival in patients after radical pancreatic surgery. The purpose of this study is to
      investigate whether perioperative epidural block and/or dexamethasone can improve 2-year
      survival in patients after pancreatic cancer surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2019</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>2Ã—2 factorial trial</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>For dexamethasone administration, all the participants, care providers, investigators, and outcomes assessors are masked. For epidural block, outcome assessors are masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>2-year overall survival</measure>
    <time_frame>Up to 2 years after surgery.</time_frame>
    <description>2-year overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative gastrointestinal complications.</measure>
    <time_frame>Up to 30 days after surgery.</time_frame>
    <description>Rate of postoperative gastrointestinal complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall postoperative complications.</measure>
    <time_frame>Up to 30 days after surgery.</time_frame>
    <description>Rate of overall postoperative complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital after surgery.</measure>
    <time_frame>Up to 30 days after surgery.</time_frame>
    <description>Length of stay in hospital after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause 30-day mortality.</measure>
    <time_frame>Up to 30 days after surgery.</time_frame>
    <description>Rate of all-cause 30-day mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life in 1- and 2-year survivors.</measure>
    <time_frame>At the end of the first and second year after surgery.</time_frame>
    <description>Quality of life is assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionaire (EORTC QLQ)-PAN26. It is a 26-item questionnaire that evaluates 9 symptoms and 5 emotional difficulties related to pancreatic cancer. Each item is scaled 0-100. High scores indicate worse symptoms and poorer quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital readmission within 2 years after surgery.</measure>
    <time_frame>Up to 2 years after surgery.</time_frame>
    <description>Rate of hospital readmission within 2 years after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year progression-free survival</measure>
    <time_frame>Up to 2 years after surgery.</time_frame>
    <description>Cancer progression is evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subjective sleep quality: Numeric Rating Scale</measure>
    <time_frame>Between 8-10 am on the first, second, and third days after surgery.</time_frame>
    <description>Subjective sleep quality is assessed with a Numeric Rating Scale (NRS, an 11-point scale where 0 indicates the best sleep and 10 the worst sleep).</description>
  </other_outcome>
  <other_outcome>
    <measure>Pain severity (at rest and with movement): Numeric Rating Scale</measure>
    <time_frame>Between 8-10 am on the first, second, and third days after surgery.</time_frame>
    <description>Pain severity is assessed with a Numeric Rating Scale (NRS, an 11-point scale where 0 indicates no pain and 10 the worst pain).</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to ambulation after surgery.</measure>
    <time_frame>Up to 30 days after surgery.</time_frame>
    <description>Time to ambulation after surgery.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to oral intake after surgery.</measure>
    <time_frame>Up to 30 days after surgery.</time_frame>
    <description>Time to oral intake after surgery.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Surgery</condition>
  <condition>Epidural Block</condition>
  <condition>Dexamethasone</condition>
  <condition>Overall Survival</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this group receive general anesthesia, without epidural block and perioperative dexamethasone. Patient-controlled intravenous analgesia is provided after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epidural block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group receive combined epidural-general anesthesia (0.375% ropivacaine for epidural block), without perioperative dexamethasone. Patient-controlled epidural analgesia is provided after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group receive dexamethasone (10 mg) before anesthesia induction and general anesthesia, without epidural block. Patient-controlled intravenous analgesia is provided after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epidural block+Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients this group receive dexamethasone (10 mg) before anesthesia induction and combined epidural-general anesthesia (0.375% ropivacaine for epidural block). Patient-controlled epidural analgesia is provided after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Epidural block</intervention_name>
    <description>Epidural block (with 0.375% ropivacaine) is performed during surgery. Patient-controlled epidural analgesia (with a mixture of 0.12% ropivacaine and 0.5 microgram/ml sufentanyl) is provided after surgery.</description>
    <arm_group_label>Epidural block</arm_group_label>
    <arm_group_label>Epidural block+Dexamethasone</arm_group_label>
    <other_name>Epidural anesthesia/analgesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone (10 mg) is administered intravenously before anesthesia induction.</description>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_label>Epidural block+Dexamethasone</arm_group_label>
    <other_name>Glucocorticoids</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥45 and &lt;90 years;

          2. Clinically diagnosed as resectable or possibly resectable pancreatic cancer and
             scheduled to undergo radical surgery;

          3. Agreed to receive epidural block and postoperative patient-controlled analgesia;

          4. Agreed to participate in the study and provided written informed consent.

        Exclusion Criteria:

          1. Clinical evidence of unresectable pancreatic cancer or plan to undergo biopsy;

          2. Previous surgery for pancreatic cancer, scheduled to undergo resurgery for recurrence
             or metastasis;

          3. Complicated with primary malignant tumor in other organ(s), either previously or at
             present;

          4. Complicated with autoimmune diseases, receiving either glucocorticoids or other
             immunosuppressants before surgery;

          5. Unable to complete preoperative evaluation due to severe dementia, language barrier,
             coma, or end-stage diseases;

          6. Severe hepatic dysfunction (Child-Pugh C), severe renal insufficiency (serum
             creatinine &gt;442 Âµmol/L or requirement of renal replacement therapy), or American
             Society of Anesthesiologists classification â‰¥Vï¼›

          7. Contradictions to epidural anesthesia, including spinal malformation, history of
             spinal surgery, coagulation disorder, suspected infection at the site of puncture, or
             severe low back pain;

          8. Other conditions that are considered unsuitable for study participation;

          9. Refused to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Xin Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong-Xin Wang, MD, PhD</last_name>
    <phone>86 (10) 83572784</phone>
    <email>wangdongxin@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhen-Zhen Xu, MD</last_name>
    <phone>86 (10) 83572460</phone>
    <email>zjxvzhenzhen@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Xin Wang, MD, PhD</last_name>
      <phone>86 (10) 83572784</phone>
      <email>wangdongxin@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhen-Zhen Xu, MD</last_name>
      <phone>86 (10) 83572460</phone>
      <email>zjxvzhenzhen@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.</citation>
    <PMID>29313949</PMID>
  </reference>
  <reference>
    <citation>Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014 Jun 1;74(11):2913-21. doi: 10.1158/0008-5472.CAN-14-0155. Erratum in: Cancer Res. 2014 Jul 15;74(14):4006.</citation>
    <PMID>24840647</PMID>
  </reference>
  <reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </reference>
  <reference>
    <citation>Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C, Yang Z, Li H, Zou X, He J. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018 Feb;30(1):1-12. doi: 10.21147/j.issn.1000-9604.2018.01.01.</citation>
    <PMID>29545714</PMID>
  </reference>
  <reference>
    <citation>Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016 Jul 2;388(10039):73-85. doi: 10.1016/S0140-6736(16)00141-0. Epub 2016 Jan 30. Review.</citation>
    <PMID>26830752</PMID>
  </reference>
  <reference>
    <citation>Yeo CJ, Cameron JL. Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Surg. 1998 Apr;383(2):129-33. Review.</citation>
    <PMID>9641885</PMID>
  </reference>
  <reference>
    <citation>Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, Schulick RD, Choti MA, Lillemoe KD, Yeo CJ. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1.</citation>
    <PMID>17114007</PMID>
  </reference>
  <reference>
    <citation>Heerkens HD, Tseng DS, Lips IM, van Santvoort HC, Vriens MR, Hagendoorn J, Meijer GJ, Borel Rinkes IH, van Vulpen M, Molenaar IQ. Health-related quality of life after pancreatic resection for malignancy. Br J Surg. 2016 Feb;103(3):257-66. doi: 10.1002/bjs.10032. Epub 2015 Nov 19.</citation>
    <PMID>26785646</PMID>
  </reference>
  <reference>
    <citation>Ohtsuka T, Yamaguchi K, Chijiiwa K, Kinukawa N, Tanaka M. Quality of life after pylorus-preserving pancreatoduodenectomy. Am J Surg. 2001 Sep;182(3):230-6.</citation>
    <PMID>11587683</PMID>
  </reference>
  <reference>
    <citation>Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, MarÃ©chal R, Van Laethem JL, Ducreux M. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016 Apr;57:10-22. doi: 10.1016/j.ejca.2015.12.026. Epub 2016 Feb 4. Review.</citation>
    <PMID>26851397</PMID>
  </reference>
  <reference>
    <citation>Chae BK, Lee HW, Sun K, Choi YH, Kim HM. The effect of combined epidural and light general anesthesia on stress hormones in open heart surgery patients. Surg Today. 1998;28(7):727-31.</citation>
    <PMID>9697266</PMID>
  </reference>
  <reference>
    <citation>PÃ¶pping DM, Elia N, Van Aken HK, Marret E, Schug SA, Kranke P, Wenk M, TramÃ¨r MR. Impact of epidural analgesia on mortality and morbidity after surgery: systematic review and meta-analysis of randomized controlled trials. Ann Surg. 2014 Jun;259(6):1056-67. doi: 10.1097/SLA.0000000000000237. Review.</citation>
    <PMID>24096762</PMID>
  </reference>
  <reference>
    <citation>Guay J. The effect of neuraxial blocks on surgical blood loss and blood transfusion requirements: a meta-analysis. J Clin Anesth. 2006 Mar;18(2):124-8.</citation>
    <PMID>16563330</PMID>
  </reference>
  <reference>
    <citation>Haughom BD, Schairer WW, Nwachukwu BU, Hellman MD, Levine BR. Does Neuraxial Anesthesia Decrease Transfusion Rates Following Total Hip Arthroplasty? J Arthroplasty. 2015 Sep;30(9 Suppl):116-20. doi: 10.1016/j.arth.2015.01.058. Epub 2015 Jun 3.</citation>
    <PMID>26077150</PMID>
  </reference>
  <reference>
    <citation>Waurick R, Van Aken H. Update in thoracic epidural anaesthesia. Best Pract Res Clin Anaesthesiol. 2005 Jun;19(2):201-13. Review.</citation>
    <PMID>15966493</PMID>
  </reference>
  <reference>
    <citation>Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology. 2008 Aug;109(2):180-7. doi: 10.1097/ALN.0b013e31817f5b73.</citation>
    <PMID>18648226</PMID>
  </reference>
  <reference>
    <citation>Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006 Oct;105(4):660-4.</citation>
    <PMID>17006061</PMID>
  </reference>
  <reference>
    <citation>Tsui BC, Rashiq S, Schopflocher D, Murtha A, Broemling S, Pillay J, Finucane BT. Epidural anesthesia and cancer recurrence rates after radical prostatectomy. Can J Anaesth. 2010 Feb;57(2):107-12. doi: 10.1007/s12630-009-9214-7.</citation>
    <PMID>19911247</PMID>
  </reference>
  <reference>
    <citation>Wuethrich PY, Hsu Schmitz SF, Kessler TM, Thalmann GN, Studer UE, Stueber F, Burkhard FC. Potential influence of the anesthetic technique used during open radical prostatectomy on prostate cancer-related outcome: a retrospective study. Anesthesiology. 2010 Sep;113(3):570-6. doi: 10.1097/ALN.0b013e3181e4f6ec.</citation>
    <PMID>20683253</PMID>
  </reference>
  <reference>
    <citation>Wang J, Guo W, Wu Q, Zhang R, Fang J. Impact of Combination Epidural and General Anesthesia on the Long-Term Survival of Gastric Cancer Patients: A Retrospective Study. Med Sci Monit. 2016 Jul 8;22:2379-85.</citation>
    <PMID>27386842</PMID>
  </reference>
  <reference>
    <citation>Cummings KC 3rd, Xu F, Cummings LC, Cooper GS. A comparison of epidural analgesia and traditional pain management effects on survival and cancer recurrence after colectomy: a population-based study. Anesthesiology. 2012 Apr;116(4):797-806. doi: 10.1097/ALN.0b013e31824674f6.</citation>
    <PMID>22273991</PMID>
  </reference>
  <reference>
    <citation>Gottschalk A, Ford JG, Regelin CC, You J, Mascha EJ, Sessler DI, Durieux ME, Nemergut EC. Association between epidural analgesia and cancer recurrence after colorectal cancer surgery. Anesthesiology. 2010 Jul;113(1):27-34. doi: 10.1097/ALN.0b013e3181de6d0d.</citation>
    <PMID>20508494</PMID>
  </reference>
  <reference>
    <citation>Grandhi RK, Lee S, Abd-Elsayed A. The Relationship Between Regional Anesthesia and Cancer: A Metaanalysis. Ochsner J. 2017 Winter;17(4):345-361. Review.</citation>
    <PMID>29230120</PMID>
  </reference>
  <reference>
    <citation>PÃ©rez-GonzÃ¡lez O, CuÃ©llar-GuzmÃ¡n LF, Soliz J, Cata JP. Impact of Regional Anesthesia on Recurrence, Metastasis, and Immune Response in Breast Cancer Surgery: A Systematic Review of the Literature. Reg Anesth Pain Med. 2017 Nov/Dec;42(6):751-756. doi: 10.1097/AAP.0000000000000662. Review.</citation>
    <PMID>28953508</PMID>
  </reference>
  <reference>
    <citation>Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, Zhang W, Song H, Bailey R, Davis D, Reid CM, Park DM, Gilbert MR. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018 Jun 11;6(1):51. doi: 10.1186/s40425-018-0371-5.</citation>
    <PMID>29891009</PMID>
  </reference>
  <reference>
    <citation>Kunicka JE, Talle MA, Denhardt GH, Brown M, Prince LA, Goldstein G. Immunosuppression by glucocorticoids: inhibition of production of multiple lymphokines by in vivo administration of dexamethasone. Cell Immunol. 1993 Jun;149(1):39-49.</citation>
    <PMID>8513511</PMID>
  </reference>
  <reference>
    <citation>Yu HC, Luo YX, Peng H, Kang L, Huang MJ, Wang JP. Avoiding perioperative dexamethasone may improve the outcome of patients with rectal cancer. Eur J Surg Oncol. 2015 May;41(5):667-73. doi: 10.1016/j.ejso.2015.01.034. Epub 2015 Feb 19.</citation>
    <PMID>25744813</PMID>
  </reference>
  <reference>
    <citation>Singh PP, Lemanu DP, Taylor MH, Hill AG. Association between preoperative glucocorticoids and long-term survival and cancer recurrence after colectomy: follow-up analysis of a previous randomized controlled trial. Br J Anaesth. 2014 Jul;113 Suppl 1:i68-73. doi: 10.1093/bja/aet577. Epub 2014 Feb 27.</citation>
    <PMID>24583820</PMID>
  </reference>
  <reference>
    <citation>Huang WW, Zhu WZ, Mu DL, Ji XQ, Nie XL, Li XY, Wang DX, Ma D. Perioperative Management May Improve Long-term Survival in Patients After Lung Cancer Surgery: A Retrospective Cohort Study. Anesth Analg. 2018 May;126(5):1666-1674. doi: 10.1213/ANE.0000000000002886.</citation>
    <PMID>29517574</PMID>
  </reference>
  <reference>
    <citation>Sandini M, Ruscic KJ, Ferrone CR, Warshaw AL, Qadan M, Eikermann M, Lillemoe KD, FernÃ¡ndez-Del Castillo C. Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer. Ann Surg Oncol. 2018 Dec;25(13):4020-4026. doi: 10.1245/s10434-018-6827-5. Epub 2018 Oct 8.</citation>
    <PMID>30298316</PMID>
  </reference>
  <reference>
    <citation>Call TR, Pace NL, Thorup DB, Maxfield D, Chortkoff B, Christensen J, Mulvihill SJ. Factors associated with improved survival after resection of pancreatic adenocarcinoma: a multivariable model. Anesthesiology. 2015 Feb;122(2):317-24. doi: 10.1097/ALN.0000000000000489.</citation>
    <PMID>25305092</PMID>
  </reference>
  <reference>
    <citation>Katayama H, Kurokawa Y, Nakamura K, Ito H, Kanemitsu Y, Masuda N, Tsubosa Y, Satoh T, Yokomizo A, Fukuda H, Sasako M. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2016 Jun;46(6):668-85. doi: 10.1007/s00595-015-1236-x. Epub 2015 Aug 20.</citation>
    <PMID>26289837</PMID>
  </reference>
  <reference>
    <citation>Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C, Beger HG, Birk D, BÃ¼chler MW, Dervenis C, Fernandez Cruz L, Friess H, Grahm AL, Jeekel J, Laugier R, Meyer D, Singer MW, Tihanyi T. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer. 1999 Jun;35(6):939-41.</citation>
    <PMID>10533475</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <reference>
    <citation>Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Traverso LW, Yeo CJ, BÃ¼chler MW. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007 Nov;142(5):761-8.</citation>
    <PMID>17981197</PMID>
  </reference>
  <reference>
    <citation>Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W, Buchler M; International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005 Jul;138(1):8-13. Review.</citation>
    <PMID>16003309</PMID>
  </reference>
  <reference>
    <citation>Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, Fan ST, Yokoyama Y, Crawford M, Makuuchi M, Christophi C, Banting S, Brooke-Smith M, Usatoff V, Nagino M, Maddern G, Hugh TJ, Vauthey JN, Greig P, Rees M, Nimura Y, Figueras J, DeMatteo RP, BÃ¼chler MW, Weitz J. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery. 2011 May;149(5):680-8. doi: 10.1016/j.surg.2010.12.002. Epub 2011 Feb 12.</citation>
    <PMID>21316725</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Xin Wang</investigator_full_name>
    <investigator_title>Chairman, Department of Anaesthesiology and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Radical resection</keyword>
  <keyword>Epidural block</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Overall survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

